Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
39.4 HKD | -5.29% | +10.67% | -19.76% |
30/04 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
29/04 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.76% | 1.4B | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points